INDIANAPOLIS (AP) -- European regulators approved the use of an imaging agent from Eli Lilly, which can help doctors diagnose Alzheimer's disease. The Indianapolis drugmaker plans to make Amyvid ...

Amyvid™ (Florbetapir F 18 Injection) Approved in European Union for Use in Patients With Cognitive Impairment Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Impairment ...

The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid (florbetapir F 18 injection) for use intravenously. The update revises the ...

INDIANAPOLIS, Oct. 19, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced they received a positive opinion ...

INDIANAPOLIS, Oct. 19, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced they received a positive opinion ...

The US Food and Drug Administration (:FDA) had approved Amyvid in April 2012. Amyvid has been designed to help detect the density of beta-amyloid plaques in patients (with cognitive impairment) who ...

While a negative scan would mean little to no neuritic plaques are present, a positive scan would point towards the presence of moderate to frequent neuritic plaques. It is to be noted that while ...

Last Friday, the FDA approved Amyvid, a drug for Alzheimer’s diagnosis that was created and developed by Penn faculty Daniel Skovronsky and Hank Kung. It dyes brain deposits of amyloid plaque, which ...

The Centers for Medicare and Medicaid Services (CMS) is pursuing a National Coverage Determination (NCD) for monoclonal antibodies that clear amyloid beta plaque from the brain, such as aducanumab ...

FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline Amyvid is the first and only radioactive diagnostic ...